Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Clears major obesity endpoints at 80 weeks
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The target reach is of more than 30 million young people and caregivers across 21 countries
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Subscribe To Our Newsletter & Stay Updated
